Miguel Ondetti discoverer of Captopril drug used to treat heart disease

Miguel Ondetti – discoverer of Captopril drug

Category : Personalities
Published by : Data Research Analyst, Worldofchemicals.com

Biography & contributions

Miguel Ondetti [Miguel Angel Ondetti] was an American chemist born on May 14, 1930 – died on August 23, 2004. Ondetti was pioneer in developing in the angiotensin-converting enzyme (ACE) inhibitors.

Ondetti was got many notable awards and medals in his research career like Alfred Burger Award in Medicinal Chemistry from American Chemical Society in the year of 1981, Thomas Alva Edison Patent Award, Research and Development Council in the year of 1983, Ciba Award for Hypertension Research, from American Heart Association 1983, Chairman’s Edward Robinson Squibb Award from E. R. Squibb & Sons, Inc 1986, Inventor of the Year Award from New Jersey Inventors Congress in the year of 1988, Perkin Medal from Society of Chemical Industry in the year of 1991, Warren Alpert Foundation Prize from Harvard Medical School in the year of 1991, Herman Bloch Award for Scientific Excellence in Industry from University of Chicago in the year of 1992, Lasker-DeBakey Clinical Medical Research Award in the year of 1999. Ondetti had discovered Captopril drug which is used to treat heart disease. Ondetti also had done research work on insulin peptide.


Fig.1] Ondetti research work on insulin peptide © Bristol-Myers Squibb Company

Ondetti et. al synthesized an amino acid molecule, succinyl-L-proline, which they thought would be an angiotensin I mimic and effectively tie up ACE.


Fig.2] Ondetti working on captopril drug © Bristol-Myers Squibb Company

Captopril

Captopril drug

Captopril is commonly marketed by Bristol-Myers Squibb company under the trade name Capoten. Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). Captopril is used to treat high blood pressure and heart failure.It decreases certain chemicals that tighten the blood vessels, so blood flows more smoothly and the heart can pump blood more efficiently. Captopril's main uses are based on its vasodilation and inhibition of some renal function activities.Chemical synthesis of captopril by treatment of L-proline with (2S)-3-acetylthio-2-methylpropanoyl chloride under basic conditions (NaOH), followed by aminolysis of the protective acetyl group to unmask the drug's free thiol. Captopril also has a relatively poor pharmacokinetic profile.

To contact the author mail: articles@worldofchemicals.com

© WOC Article